PROTAGONIST THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.15 USD | +1.99% |
|
-1.80% | +9.68% |
Chart calendar Protagonist Therapeutics, Inc.
1675b6.RadANoq208imKVal4WCpq90i2dxh6FbRgdTObzQf770.GsoIV9v6oIT3cGLzkDXg_utXt49VshHg06KnPwJFiIUmlhF7vMCKgJBnHw~0a0d2a099f4f66833f213d8189a25479
Upcoming events on Protagonist Therapeutics, Inc.
Past events on Protagonist Therapeutics, Inc.
| 28/03/2024 17:00 | H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference |
| 26/03/2024 17:30 | Napa Valley Biotech Forum |
| 11/03/2024 | Jefferies Biotech on the Bay Summit |
| 10/03/2024 | American Academy of Dermatology Meeting |
| 27/02/2024 21:05 | Q4 2023 Earnings Release |
| 08/02/2024 14:00 | Guggenheim Healthcare Talks Biotechnology Conference |
| 31/01/2024 21:30 | Business Update Call |
| 09/01/2024 17:45 | JPMorgan Healthcare Conference |
| 11/12/2023 18:30 | American Society of Hematology Meeting - Session Name: 634 |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Session Name: 634 |
| 10/12/2023 01:30 | American Society of Hematology Meeting - Session Name: 113 |
| 09/12/2023 18:30 | American Society of Hematology Meeting - Session Name: 904 |
| 14/11/2023 09:00 | Jefferies London Healthcare Conference - Fireside Chat |
| 09/11/2023 19:25 | Truist Securities Healthcare Conference - Panel |
| 06/11/2023 | J.P. Morgan Equity Opportunities Forum |
| 06/11/2023 16:10 | Guggenheim Securities Inflammation & Immunology Conference - Fireside Chat |
| 02/11/2023 04:00 | Q3 2023 Earnings Release |
| 01/11/2023 | Myeloproliferative Neoplasms International Congress |
| 12/09/2023 05:00 | H.C. Wainwright Global Investment Conference |
| 03/08/2023 21:05 | Q2 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,23 1,74 -86.69% | 28,6 25,7 11.45% | 27,4 23,2 17.93% | 26,6 31,4 -15.46% | 60,0 30,0 100% | 208 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -63,7 -68,7 7.22% | -125 -135 7.38% | 0,00 0,00 - | -92,7 -96,0 3.46% | -144 |
|
EBIT Million USD | Released Forecast Spread | -80,5 -81,8 1.55% | -64,5 -65,4 1.29% | -126 -128 1.54% | -131 -125 -5.35% | -93,7 -127 26.5% | 40,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -77,9 -79,3 1.83% | -64,8 -64,1 -1.11% | -126 -128 2.06% | -127 -127 -0.41% | -79,0 -116 31.76% | 83,4 |
|
Net income Million USD | Released Forecast Spread | -77,2 -77,9 0.89% | -66,2 -66,2 0.04% | -126 -128 1.93% | -127 -123 -3.53% | -79,0 -115 31.24% | 44,9 |
|
EPS USD | Released Forecast Spread | -2,98 -3,00 0.6% | -1,92 -1,94 0.84% | -2,71 -2,73 0.78% | -2,60 -2,49 -4.44% | -1,39 -2,02 31.28% | 0,72 |
| Announcement Date | 10/03/20 | 10/03/21 | 28/02/22 | 15/03/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 8,62 4,44 94.19% | 25,7 17,1 50.86% | 0,86 0,38 124.09% | 0,00 0,00 - | 0,00 5,00 - | 0,00 1,67 - | 0,00 0,00 - | 0,00 0,00 - | 60,0 30,0 100% | 120 | 60,0 | 0,00 | 9,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -36,8 -46,0 20.04% | -20,9 -50,0 58.28% | -41,2 -52,0 20.8% | -32,0 -43,0 25.5% | -36,3 -33,0 -9.88% | -35,8 -37,0 3.32% | -42,1 -37,0 -13.83% | -38,1 -43,0 11.44% | 23,3 21,0 10.94% | -38,0 | -38,0 | -39,0 | -30,0 | |
|
EBIT Million USD | Released Forecast Spread | -37,0 -39,0 5.05% | -21,1 -27,8 24.07% | -41,4 -46,3 10.55% | -32,3 -43,3 25.35% | -36,5 -29,0 -25.97% | -36,0 -36,3 0.65% | -42,4 -36,5 -15.94% | -38,3 -42,6 9.96% | 23,0 -10,1 328.49% | 36,9 | 30,6 | -40,6 | -30,8 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -36,9 -39,4 6.41% | -20,9 -31,6 33.77% | -41,0 -48,9 16.01% | -31,2 -41,7 25.09% | -34,2 -33,6 -1.71% | -33,7 -33,5 -0.69% | -38,5 -35,0 -9.97% | -34,1 -39,7 14.11% | 27,3 -8,04 440.04% | 114 | -37,1 | -38,4 | -16,8 | |
|
Net income Million USD | Released Forecast Spread | -36,9 -39,3 6.09% | -20,9 -30,4 31.15% | -41,0 -45,9 10.65% | -31,2 -43,0 27.39% | -34,2 -29,4 -16.27% | -33,7 -35,9 6.05% | -38,5 -35,5 -8.2% | -34,1 -40,2 15.17% | 27,3 -7,61 459.24% | 39,3 | 32,3 | -38,4 | -28,1 | |
|
EPS USD | Released Forecast Spread | -0,77 -0,79 2.35% | -0,43 -0,63 31.57% | -0,84 -0,94 10.17% | -0,64 -0,87 26.31% | -0,69 -0,59 -16.49% | -0,67 -0,73 7.78% | -0,68 -0,65 -5.22% | -0,58 -0,69 16.27% | 0,44 -0,14 406.9% | 1,19 | 0,34 | -0,63 | -0,51 | -0,77 |
| Announcement Date | 28/02/22 | 04/05/22 | 04/08/22 | 08/11/22 | 15/03/23 | 04/05/23 | 03/08/23 | 02/11/23 | 27/02/24 | - | - | - | - | - |
More events
Past sector events for Protagonist Therapeutics, Inc.
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 06:00 | BB BIOTECH AG: Q1 2024 Earnings Release |
| 25/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 25/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 25/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 12:00 | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 07:00 | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PTGX Stock
- Calendar Protagonist Therapeutics, Inc.
